Nathalie Veronica Fernandez Villalobos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nathalie Veronica Fernandez Villalobos has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Eliane Rohner
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
47 shared publications - Matthias Egger
Institute of Social and Preventive Medicine, University of Bern , Bern
46 shared publications - Yann Ruffieux
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
46 shared publications - Andreas D. Haas
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
45 shared publications - Chido Chinogurei
Centre for Integrated Data and Epidemiological Research, School of Public Health, University of Cape Town , Cape Town
45 shared publications - Gary Maartens
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town
45 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Elsevier in IJID Regions
- Vol. 21
Genotype-specific agreement and accuracy of human papillomavirus DNA detection using AnyplexTM II HPV28 and XpertTM HPV among women with HIV in Lusaka, Zambia: a diagnostic accuracy analysis
- 25 September 2026
- Published by Elsevier in IJID Regions
- Vol. 21
Open AccessGenotype-specific agreement and accuracy of human papillomavirus DNA detection using AnyplexTM II HPV28 and XpertTM HPV among women with HIV in Lusaka, Zambia: a diagnostic accuracy analysis
- Open Access
Documenting HIV service delivery and adoption of evidence-based practices in HIV care programs: A protocol for a cross-sectional survey of HIV clinics participating in the International epidemiology Databases to Evaluate AIDS (IeDEA)
Introduction: HIV care and treatment programs around the world continue to evolve in response to changes in clinical guidelines, evidence-based practices, domestic and donor funding for the HIV response, new technological developments, and changing weather patterns. Since 2009, the International epidemiology Databases to Evaluate AIDS (IeDEA) research consortium has conducted periodic surveys to document the characteristics of participating clinics and the availability of HIV-related services across diverse settings—information that provides important context for understanding variations and trends in HIV care outcomes. This paper describes the protocol for IeDEA’s 2026 site assessment survey, launched in August 2026. Methods and analysis: This cross-sectional descriptive study aims to document HIV-related services and practices among clinics in 42 countries. The survey explores the characteristics and services provided at HIV care and treatment sites participating in IeDEA in 2026, along with real-world adoption and implementation of evidence-based service delivery strategies for people living with or at risk of HIV. Designed for self-administration, the survey questionnaire was developed through two complementary processes: a review of questions and data collected through IeDEA’s prior consortium-wide surveys and an open call to IeDEA investigators for new survey content to advance a timely implementation science agenda relevant to the global HIV community. Survey materials and links to an online REDCap questionnaire will be distributed to 235 eligible clinics across IeDEA in September 2026, with a deadline of November 30, 2026, for completion. Planned analyses will examine the following topics: HIV care amidst funding constraints; the roll-out of differentiated service delivery models; pre-exposure HIV prophylaxis; long-acting injectable antiretroviral therapy (ART); prevention, screening and/or treatment services for viral hepatitis, mental health and substance use disorders, cardiovascular disease, and cancers among PLHIV; the integration of HIV care with other health services; and clinic vulnerability to extreme weather events. Ethics and dissemination: A “non-human subjects” research designation was determined by the Vanderbilt University Medical Center Human Research Protections Program. Survey findings will be shared with local partners and stakeholders across IeDEA, disseminated at regional and global conferences, and published in peer-reviewed journals. Strengths and limitations of this study: Strengths of this study include gathering data for a global cohort of 235 HIV clinics across 42 low-, middle- and high-income countries, reflecting real-world adoption and implementation of treatment guidelines and evidence-based practices for HIV prevention, care and management across diverse settings during a period of substantial changes in funding for the HIV response. Further strengths include a rigorous process for survey development that combined an in-depth review of data and findings from prior International epidemiology Databases to Evaluate AIDS (IeDEA) surveys with new investigator-driven content focused on implementation science questions related to the HIV response and key gaps in the literature. Study limitations include potential recall and social desirability biases inherent in self-reported data, as well as selection biases that may determine clinic participation. Additionally, while clinics participating in the global IeDEA research consortium are reflective of real-world HIV care delivery, they may not be nationally or regionally representative.
Open AccessDocumenting HIV service delivery and adoption of evidence-based practices in HIV care programs: A protocol for a cross-sectional survey of HIV clinics participating in the International epidemiology Databases to Evaluate AIDS (IeDEA)
Introduction: HIV care and treatment programs around the world continue to evolve in response to changes in clinical guidelines, evidence-based practices, domestic and donor funding for the HIV response, new technological developments, and changing weather patterns. Since 2009, the International epidemiology Databases to Evaluate AIDS (IeDEA) research consortium has conducted periodic surveys to document the characteristics of participating clinics and the availability of HIV-related services across diverse settings—information that provides important context for understanding variations and trends in HIV care outcomes. This paper describes the protocol for IeDEA’s 2026 site assessment survey, launched in August 2026. Methods and analysis: This cross-sectional descriptive study aims to document HIV-related services and practices among clinics in 42 countries. The survey explores the characteristics and services provided at HIV care and treatment sites participating in IeDEA in 2026, along with real-world adoption and implementation of evidence-based service delivery strategies for people living with or at risk of HIV. Designed for self-administration, the survey questionnaire was developed through two complementary processes: a review of questions and data collected through IeDEA’s prior consortium-wide surveys and an open call to IeDEA investigators for new survey content to advance a timely implementation science agenda relevant to the global HIV community. Survey materials and links to an online REDCap questionnaire will be distributed to 235 eligible clinics across IeDEA in September 2026, with a deadline of November 30, 2026, for completion. Planned analyses will examine the following topics: HIV care amidst funding constraints; the roll-out of differentiated service delivery models; pre-exposure HIV prophylaxis; long-acting injectable antiretroviral therapy (ART); prevention, screening and/or treatment services for viral hepatitis, mental health and substance use disorders, cardiovascular disease, and cancers among PLHIV; the integration of HIV care with other health services; and clinic vulnerability to extreme weather events. Ethics and dissemination: A “non-human subjects” research designation was determined by the Vanderbilt University Medical Center Human Research Protections Program. Survey findings will be shared with local partners and stakeholders across IeDEA, disseminated at regional and global conferences, and published in peer-reviewed journals. Strengths and limitations of this study: Strengths of this study include gathering data for a global cohort of 235 HIV clinics across 42 low-, middle- and high-income countries, reflecting real-world adoption and implementation of treatment guidelines and evidence-based practices for HIV prevention, care and management across diverse settings during a period of substantial changes in funding for the HIV response. Further strengths include a rigorous process for survey development that combined an in-depth review of data and findings from prior International epidemiology Databases to Evaluate AIDS (IeDEA) surveys with new investigator-driven content focused on implementation science questions related to the HIV response and key gaps in the literature. Study limitations include potential recall and social desirability biases inherent in self-reported data, as well as selection biases that may determine clinic participation. Additionally, while clinics participating in the global IeDEA research consortium are reflective of real-world HIV care delivery, they may not be nationally or regionally representative.
- Open Access
- 12 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (12) , ofaf693
Immunodeficiency, HIV Viremia, and Incident Anal Cancer Among People With HIV in South Africa
Among 130 992 people with HIV (PWH) in South Africa, 60 anal cancers were diagnosed. Lower CD4 counts and, to a lesser extent, higher HIV RNA viral loads were associated with an increased anal cancer risk. Maintaining high CD4 counts may contribute to anal cancer prevention among PWH in South Africa.
- 12 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (12) , ofaf693
Open AccessImmunodeficiency, HIV Viremia, and Incident Anal Cancer Among People With HIV in South Africa
Among 130 992 people with HIV (PWH) in South Africa, 60 anal cancers were diagnosed. Lower CD4 counts and, to a lesser extent, higher HIV RNA viral loads were associated with an increased anal cancer risk. Maintaining high CD4 counts may contribute to anal cancer prevention among PWH in South Africa.
- Open Access
- 29 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf537
Anal Cancer Incidence Rates Among Men and Women With and Without HIV in South Africa
Background: More than 7.5 million people in South Africa have HIV, but little is known about the association of HIV and anal cancer incidence. We examined anal cancer incidence in a large South African cohort of insured men and women. Methods: We conducted a cohort study using reimbursement claims data from a South African medical insurance scheme (01/2011-07/2020) to assess anal cancer rates among people with and without HIV aged ≥18 years. We estimated adjusted hazard ratios (aHRs) for the association of HIV and incident anal cancer using flexible parametric survival models. Covariates included sex, age, calendar year, a history of genital warts and other sexually transmitted infections, and in women, cervical precancer. Results: We included 1 068 915 people of whom 69 985 (7%) were living with HIV. Over 3 933 145 person-years, 122 anal cancers were diagnosed (crude rate: 3.1/100 000 person-years; 95% confidence intervals [CI] 2.6–3.7). People with HIV had a 4-fold higher anal cancer risk than people without HIV (aHR 4.43; 95% CI 2.44–8.04). While anal cancer rates were similar among men and women, older age (≥65 vs 45–54 years; aHR 5.01; 95% CI: 2.94–8.53), a history of genital warts (aHR 7.56; 95% CI: 2.28–25.07), and among women, a prior cervical precancer diagnosis (aHR 5.70; 95% CI 1.75–18.58) were associated with a higher anal cancer risk. Conclusions: In South Africa, men and women with HIV, older individuals, people with a history of genital warts, and women with a prior cervical precancer diagnosis might benefit from prioritized access to anal cancer screening.
- 29 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf537
Open AccessAnal Cancer Incidence Rates Among Men and Women With and Without HIV in South Africa
Background: More than 7.5 million people in South Africa have HIV, but little is known about the association of HIV and anal cancer incidence. We examined anal cancer incidence in a large South African cohort of insured men and women. Methods: We conducted a cohort study using reimbursement claims data from a South African medical insurance scheme (01/2011-07/2020) to assess anal cancer rates among people with and without HIV aged ≥18 years. We estimated adjusted hazard ratios (aHRs) for the association of HIV and incident anal cancer using flexible parametric survival models. Covariates included sex, age, calendar year, a history of genital warts and other sexually transmitted infections, and in women, cervical precancer. Results: We included 1 068 915 people of whom 69 985 (7%) were living with HIV. Over 3 933 145 person-years, 122 anal cancers were diagnosed (crude rate: 3.1/100 000 person-years; 95% confidence intervals [CI] 2.6–3.7). People with HIV had a 4-fold higher anal cancer risk than people without HIV (aHR 4.43; 95% CI 2.44–8.04). While anal cancer rates were similar among men and women, older age (≥65 vs 45–54 years; aHR 5.01; 95% CI: 2.94–8.53), a history of genital warts (aHR 7.56; 95% CI: 2.28–25.07), and among women, a prior cervical precancer diagnosis (aHR 5.70; 95% CI 1.75–18.58) were associated with a higher anal cancer risk. Conclusions: In South Africa, men and women with HIV, older individuals, people with a history of genital warts, and women with a prior cervical precancer diagnosis might benefit from prioritized access to anal cancer screening.
- Open Access
- 7 July 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (S3) , e26477
Scale of differentiated service delivery implementation in HIV care facilities in low‐ and middle‐income countries: a global facility survey
Introduction: In 2016, the World Health Organization recommended differentiated service delivery (DSD) as a client‐centred approach to simplify HIV care in frequency and intensity, thus reducing the clinic visit burden on individuals and HIV programmes. We describe the scale of DSD implementation among HIV facilities in low‐ and middle‐income countries (LMICs) in Latin America, Africa and the Asia‐Pacific before the COVID‐19 pandemic.Methods: We analysed facility‐level survey data from HIV care facilities participating in the International epidemiology Databases to Evaluate AIDS consortium in 2019. We used descriptive statistics to summarise the availability of DSD, multi‐month dispensing (MMD) and DSD for HIV treatment models. We explored factors associated with DSD implementation using multivariable models.Results: We included 175 facilities in the Asia‐Pacific (n = 30), Latin America (n = 8), Central Africa (n = 21), East Africa (n = 74), Southern Africa (n = 28) and West Africa (n = 14). Overall, 133 facilities (76%) reported implementing DSD. Of these, 91% offered DSD for HIV treatment, 61% for HIV testing and 59% for antiretroviral therapy (ART) initiation. The most common duration of ART refills for clinically stable clients was 3MMD, (70%), followed by monthly (14%) and 6MMD (10%). Facility‐based individual models were the most frequently available DSD for the HIV treatment model (82%), followed by client‐managed group models (60%). Out‐of‐facility individual models were available at 48% of facilities. Facility‐based individual models were particularly common among facilities in East (92%) and Southern Africa (96%). Facilities in medium and high HIV prevalence countries, and those with 3MMD, were more likely to implement DSD.Conclusions: In 2019, DSD was available in most HIV care facilities globally but was not evenly implemented across regions and HIV services. Most offered facility‐based DSD for HIV treatment models and 3MMD for clinically stable clients. Efforts to expand DSD for HIV testing and ART initiation and to offer longer MMD can improve long‐term retention in care of people living with HIV in LMICs, while further alleviating the operational burden on healthcare services. These findings from the pre‐COVID‐19 era underline the need for strengthening DSD in HIV care, which remains at the centre of current efforts towards client‐centred care.
- 7 July 2025
- Published by Wiley in Journal of the International AIDS Society
- Vol. 28 (S3) , e26477
Open AccessScale of differentiated service delivery implementation in HIV care facilities in low‐ and middle‐income countries: a global facility survey
Introduction: In 2016, the World Health Organization recommended differentiated service delivery (DSD) as a client‐centred approach to simplify HIV care in frequency and intensity, thus reducing the clinic visit burden on individuals and HIV programmes. We describe the scale of DSD implementation among HIV facilities in low‐ and middle‐income countries (LMICs) in Latin America, Africa and the Asia‐Pacific before the COVID‐19 pandemic.Methods: We analysed facility‐level survey data from HIV care facilities participating in the International epidemiology Databases to Evaluate AIDS consortium in 2019. We used descriptive statistics to summarise the availability of DSD, multi‐month dispensing (MMD) and DSD for HIV treatment models. We explored factors associated with DSD implementation using multivariable models.Results: We included 175 facilities in the Asia‐Pacific (n = 30), Latin America (n = 8), Central Africa (n = 21), East Africa (n = 74), Southern Africa (n = 28) and West Africa (n = 14). Overall, 133 facilities (76%) reported implementing DSD. Of these, 91% offered DSD for HIV treatment, 61% for HIV testing and 59% for antiretroviral therapy (ART) initiation. The most common duration of ART refills for clinically stable clients was 3MMD, (70%), followed by monthly (14%) and 6MMD (10%). Facility‐based individual models were the most frequently available DSD for the HIV treatment model (82%), followed by client‐managed group models (60%). Out‐of‐facility individual models were available at 48% of facilities. Facility‐based individual models were particularly common among facilities in East (92%) and Southern Africa (96%). Facilities in medium and high HIV prevalence countries, and those with 3MMD, were more likely to implement DSD.Conclusions: In 2019, DSD was available in most HIV care facilities globally but was not evenly implemented across regions and HIV services. Most offered facility‐based DSD for HIV treatment models and 3MMD for clinically stable clients. Efforts to expand DSD for HIV testing and ART initiation and to offer longer MMD can improve long‐term retention in care of people living with HIV in LMICs, while further alleviating the operational burden on healthcare services. These findings from the pre‐COVID‐19 era underline the need for strengthening DSD in HIV care, which remains at the centre of current efforts towards client‐centred care.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Table S9 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S9 shows hazard ratios for prostate cancer diagnosis, with no left-truncation at first HIV indicator.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S9 shows hazard ratios for prostate cancer diagnosis, with no left-truncation at first HIV indicator.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Table S5 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S5 shows characteristics at diagnosis of prostate cancer, by population group.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S5 shows characteristics at diagnosis of prostate cancer, by population group.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Cohort characteristics by HIV status and overall.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Cohort characteristics by HIV status and overall.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S1 shows degrees of freedom chosen for the natural spline bases in the Royston-Parmar flexible parametric survival models.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Table S1 shows degrees of freedom chosen for the natural spline bases in the Royston-Parmar flexible parametric survival models.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Figure S1 shows hazard ratios for prostate cancer diagnosis over follow-up time.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Figure S1 shows hazard ratios for prostate cancer diagnosis over follow-up time.